WALTHAM, Mass., Oct. 27, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended October 2, 2021.
Third Quarter 2021 Highlights
- Third quarter revenue increased 9% to $9.33 billion.
- Third quarter GAAP diluted earnings per share (EPS) was $4.79.
- Third quarter adjusted EPS was $5.76.
- The company continued to expand capacity and capabilities to better serve customers. Our Pharma Services business brought additional capacity online to support vaccine and therapy production. In South Korea, we opened a Bioprocess Design Center, to advance bioprocessing innovation and collaboration with biopharma customers, and as part of the previously announced strategic partnership with CSL Limited, we assumed operating responsibility of a new state-of-the-art biologics site in Lengnau, Switzerland. Additionally, in partnership with the U.S. Department of Defense, we are building a new manufacturing site in North Carolina to ensure reliable domestic production of pipette tips which are used for liquid handling in research and diagnostic laboratories.
- Building on our environmental social and governance initiatives and to further enable customers to achieve their own sustainability goals, the company committed to expand use of ACT Label for its entire cold temperature storage portfolio by the end of 2021. Additionally, the company extended its support of COVID-19 testing at historically black colleges and universities (HBCUs) to deliver accurate COVID-19 testing to all students and staff, helping to ensure campus safety and the ability to confidently deliver in-person learning.
Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”
“Our incredibly strong performance in the third quarter demonstrates our proven growth strategy powered by our PPI Business System,” said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. “We continue to deliver exceptional performance in revenue, earnings and free cash flow. And we are launching innovative new products and expanding our capabilities and capacity to enhance our customer value proposition.”
Casper added, “Our team executed at a very high level during the first nine months of the year, and we are on track to deliver another outstanding year and set the company up for an even brighter future.”
Third Quarter 2021
Revenue for the quarter grew 9% to $9.33 billion in 2021, versus $8.52 billion in 2020. Organic revenue growth was 7%; acquisitions increased revenue by 1% and currency translation increased revenue by 1%. Organic revenue growth from the base business was 10%. COVID-19 response revenue was $2.05 billion.
GAAP Earnings Results
GAAP diluted EPS in the third quarter of 2021 was $4.79, versus $4.84 in the same quarter last year. GAAP operating income for the third quarter of 2021 was $2.28 billion, compared with $2.43 billion in the year-ago quarter. GAAP operating margin was 24.4%, compared with 28.5% in the third quarter of 2020.
Non-GAAP Earnings Results
Adjusted EPS in the third quarter of 2021 increased 2% to $5.76, versus $5.63 in the third quarter of 2020. Adjusted operating income for the third quarter of 2021 was $2.78 billion, compared with $2.80 billion in the year-ago quarter. Adjusted operating margin was 29.8%, compared with 32.9% in the third quarter of 2020.
2021 Guidance Update
Thermo Fisher is raising its 2021 revenue and earnings guidance. The company is raising its revenue guidance by $1.2 billion to $37.1 billion; this would result in 15% revenue growth over 2020. The company is raising its adjusted EPS guidance by $1.30 to $23.37, which would represent 20% growth year over year.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the company’s four business segments, as highlighted below. Since these results are used for this purpose, they are also considered to be prepared in accordance with GAAP.
Life Sciences Solutions Segment
Life Sciences Solutions Segment revenue grew 9% to $3.72 billion in the third quarter of 2021, compared with revenue of $3.42 billion in the third quarter of 2020. Segment adjusted operating margin was 48.9%, versus 54.9% in the 2020 quarter.
Analytical Instruments Segment
Analytical Instruments Segment revenue grew 11% to $1.48 billion in the third quarter of 2021, compared with revenue of $1.34 billion in the third quarter of 2020. Segment adjusted operating margin was 17.8%, versus 12.8% in the 2020 quarter.
Specialty Diagnostics Segment
Specialty Diagnostics Segment revenue was $1.36 billion in the third quarter of 2021, compared with revenue of $1.43 billion in the third quarter of 2020. Segment adjusted operating margin was 22.7%, versus 27.9% in the 2020 quarter.
Laboratory Products and Services Segment
Laboratory Products and Services Segment revenue grew 12% to $3.49 billion in the third quarter of 2021, compared with revenue of $3.11 billion in the third quarter of 2020. Segment adjusted operating margin was 11.0%, versus 11.4% in the 2020 quarter.
Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS, adjusted operating income and adjusted operating margin, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and the impact of significant tax audits or events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We also use a non-GAAP measure, free cash flow, which is operating cash flow, excluding net capital expenditures to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts.
For example:
We exclude costs and tax effects associated with restructuring activities, such as reducing overhead and consolidating facilities. We believe that the costs related to these restructuring activities are not indicative of our normal operating costs.
We exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs. We exclude these costs because we do not believe they are indicative of our normal operating costs.
We exclude the expense and tax effects associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Based on acquisitions closed through the end of the third quarter of 2021, adjusted EPS will exclude approximately $3.36 of expense for the amortization of acquisition-related intangible assets. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
We also exclude certain gains/losses and related tax effects, the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate changes), which are either isolated or cannot be expected to occur again with any predictability and that we believe are not indicative of our normal operating gains and losses. For example, we exclude gains/losses from items such as the sale of a business or real estate, gains or losses on significant litigation-related matters, gains on curtailments of pension plans and the early retirement of debt.
We also report free cash flow, which is operating cash flow, excluding net capital expenditures to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities.
Thermo Fisher Scientific’s management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring the company’s core operating performance and comparing such performance to that of prior periods and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes.
The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying tables. Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today, October 27, 2021, at 8:30 a.m. Eastern time. To listen, dial (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. The conference ID is 6971977. You may also listen to the call live on our website, www.thermofisher.com, by clicking on “Investors.” You will find this press release, including the accompanying reconciliation of non-GAAP financial measures and related information, in that section of our website under “Financial Results.” An audio archive of the call will be available under “Webcasts and Presentations” through Friday, November 12, 2021.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our pending acquisition of PPD, Inc., may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
###
Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
|
Condensed Consolidated Statement of Income (unaudited) (a)(b) |
||||||||||||||
|
Three Months Ended |
||||||||||||||
|
October 2, |
% of |
September 26, |
% of |
|||||||||||
|
(In millions except per share amounts) |
2021 |
Revenues |
2020 |
Revenues |
||||||||||
|
Revenues |
$ |
9,330 |
$ |
8,521 |
||||||||||
|
Costs and Operating Expenses: |
||||||||||||||
|
Cost of revenues (c) |
4,533 |
48.6 |
% |
4,065 |
47.7 |
% |
||||||||
|
Selling, general and administrative expenses (d) |
1,727 |
18.5 |
% |
1,303 |
15.3 |
% |
||||||||
|
Amortization of acquisition-related intangible assets |
423 |
4.6 |
% |
414 |
4.9 |
% |
||||||||
|
Research and development expenses |
351 |
3.8 |
% |
296 |
3.5 |
% |
||||||||
|
Restructuring and other costs (e) |
18 |
0.2 |
% |
17 |
0.2 |
% |
||||||||
|
7,052 |
75.6 |
% |
6,095 |
71.5 |
% |
|||||||||
|
Operating Income |
2,278 |
24.4 |
% |
2,426 |
28.5 |
% |
||||||||
|
Interest Income |
9 |
9 |
||||||||||||
|
Interest Expense |
(128) |
(144) |
||||||||||||
|
Other Income (Expense) (f) |
14 |
(39) |
||||||||||||
|
Income Before Income Taxes |
2,173 |
2,252 |
||||||||||||
|
Provision for Income Taxes (g) |
(271) |
(319) |
||||||||||||
|
Net Income |
$ |
1,902 |
20.4 |
% |
$ |
1,933 |
22.7 |
% |
||||||
|
Earnings per Share: |
||||||||||||||
|
Basic |
$ |
4.83 |
$ |
4.88 |
||||||||||
|
Diluted |
$ |
4.79 |
$ |
4.84 |
||||||||||
|
Weighted Average Shares: |
||||||||||||||
|
Basic |
394 |
396 |
||||||||||||
|
Diluted |
397 |
399 |
||||||||||||
|
Reconciliation of Adjusted Operating Income and Adjusted Operating Margin |
||||||||||||||
|
GAAP Operating Income (a) |
$ |
2,278 |
24.4 |
% |
$ |
2,426 |
28.5 |
% |
||||||
|
Cost of Revenues Charges (c) |
— |
0.0 |
% |
1 |
0.0 |
% |
||||||||
|
Selling, General and Administrative Charges (Credits) (d) |
59 |
0.6 |
% |
(55) |
-0.7 |
% |
||||||||
|
Restructuring and Other Costs (e) |
18 |
0.2 |
% |
17 |
0.2 |
% |
||||||||
|
Amortization of Acquisition-related Intangible Assets |
423 |
4.6 |
% |
414 |
4.9 |
% |
||||||||
|
Adjusted Operating Income (b) |
$ |
2,778 |
29.8 |
% |
$ |
2,803 |
32.9 |
% |
||||||
|
Reconciliation of Adjusted Net Income |
||||||||||||||
|
GAAP Net Income (a) |
$ |
1,902 |
$ |
1,933 |
||||||||||
|
Cost of Revenues Charges (c) |
— |
1 |
||||||||||||
|
Selling, General and Administrative Charges (Credits) (d) |
59 |
(55) |
||||||||||||
|
Restructuring and Other Costs (e) |
18 |
17 |
||||||||||||
|
Amortization of Acquisition-related Intangible Assets |
423 |
414 |
||||||||||||
|
Other (Income) Expense (f) |
(5) |
40 |
||||||||||||
|
Benefit from Income Taxes (g) |
(108) |
(100) |
||||||||||||
|
Adjusted Net Income (b) |
$ |
2,289 |
$ |
2,250 |
||||||||||
|
Reconciliation of Adjusted Earnings per Share |
||||||||||||||
|
GAAP Diluted EPS (a) |
$ |
4.79 |
$ |
4.84 |
||||||||||
|
Cost of Revenues Charges, Net of Tax (c) |
0.00 |
0.00 |
||||||||||||
|
Selling, General and Administrative Charges (Credits), Net of Tax (d) |
0.13 |
(0.11) |
||||||||||||
|
Restructuring and Other Costs, Net of Tax (e) |
0.03 |
0.03 |
||||||||||||
|
Amortization of Acquisition-related Intangible Assets, Net of Tax |
0.84 |
0.82 |
||||||||||||
|
Other (Income) Expense, Net of Tax (f) |
(0.01) |
0.08 |
||||||||||||
|
Benefit from Income Taxes (g) |
(0.02) |
(0.03) |
||||||||||||
|
Adjusted EPS (b) |
$ |
5.76 |
$ |
5.63 |
||||||||||
|
Reconciliation of Free Cash Flow |
||||||||||||||
|
GAAP Net Cash Provided by Operating Activities (a) |
$ |
2,650 |
$ |
2,708 |
||||||||||
|
Purchases of Property, Plant and Equipment |
(524) |
(366) |
||||||||||||
|
Proceeds from Sale of Property, Plant and Equipment |
4 |
1 |
||||||||||||
|
Free Cash Flow |
$ |
2,130 |
$ |
2,343 |
||||||||||
|
Segment Data |
Three Months Ended |
|||||||||||||
|
October 2, |
% of |
September 26, |
% of |
|||||||||||
|
(In millions) |
2021 |
Revenues |
2020 |
Revenues |
||||||||||
|
Revenues |
||||||||||||||
|
Life Sciences Solutions |
$ |
3,721 |
39.9 |
% |
$ |
3,424 |
40.2 |
% |
||||||
|
Analytical Instruments |
1,476 |
15.8 |
% |
1,336 |
15.7 |
% |
||||||||
|
Specialty Diagnostics |
1,362 |
14.6 |
% |
1,430 |
16.8 |
% |
||||||||
|
Laboratory Products and Services |
3,487 |
37.4 |
% |
3,112 |
36.5 |
% |
||||||||
|
Eliminations |
(716) |
-7.7 |
% |
(781) |
-9.2 |
% |
||||||||
|
Consolidated Revenues |
$ |
9,330 |
100.0 |
% |
$ |
8,521 |
100.0 |
% |
||||||
|
Operating Income and Operating Margin |
||||||||||||||
|
Life Sciences Solutions |
$ |
1,821 |
48.9 |
% |
$ |
1,879 |
54.9 |
% |
||||||
|
Analytical Instruments |
264 |
17.8 |
% |
171 |
12.8 |
% |
||||||||
|
Specialty Diagnostics |
310 |
22.7 |
% |
398 |
27.9 |
% |
||||||||
|
Laboratory Products and Services |
383 |
11.0 |
% |
355 |
11.4 |
% |
||||||||
|
Subtotal Reportable Segments |
2,778 |
29.8 |
% |
2,803 |
32.9 |
% |
||||||||
|
Cost of Revenues Charges (c) |
— |
0.0 |
% |
(1) |
0.0 |
% |
||||||||
|
Selling, General and Administrative (Charges) Credits (d) |
(59) |
-0.6 |
% |
55 |
0.7 |
% |
||||||||
|
Restructuring and Other Costs (e) |
(18) |
-0.2 |
% |
(17) |
-0.2 |
% |
||||||||
|
Amortization of Acquisition-related Intangible Assets |
(423) |
-4.6 |
% |
(414) |
-4.9 |
% |
||||||||
|
GAAP Operating Income (a) |
$ |
2,278 |
24.4 |
% |
$ |
2,426 |
28.5 |
% |
||||||
|
(a) “GAAP” (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP). |
||||||||||||||
|
(b) Adjusted results are non-GAAP measures and, for income measures, exclude certain charges to cost of revenues (see note (c) for details); certain credits/charges to selling, general and administrative expenses (see note (d) for details); amortization of acquisition-related intangible assets; restructuring and other costs (see note (e) for details); certain other gains or losses that are either isolated or cannot be expected to occur again with any predictability (see note (f) for details); and the tax consequences of the preceding items and certain other tax items (see note (g) for details). |
||||||||||||||
|
(c) Reported results in 2020 include accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. |
||||||||||||||
|
(d) Reported results in 2021 and 2020 include certain third-party expenses (credits), principally transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions; charges (credits) for changes in estimates of contingent acquisition consideration; and costs associated with product liability litigation. |
||||||||||||||
|
(e) Reported results in 2021 and 2020 include restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in 2021 also include $4 of credits for the settlement of environmental-related matters, offset in part by $3 of net charges for pre-acquisition related matters. Reported results in 2020 also include $10 of charges for impairment of acquired technology. |
||||||||||||||
|
(f) Reported results in 2021 and 2020 include gains on investments and charges for the amortization of bridge loan commitment fees related to pending/terminated acquisitions. Reported results in 2020 also include $5 of net charges for the settlement/curtailment of pension plans. |
||||||||||||||
|
(g) Reported provision for income taxes in 2021 and 2020 includes incremental tax benefit for the pre-tax reconciling items between GAAP and adjusted net income. Reported results in 2020 also include $11 of incremental tax benefit from adjusting the company’s non-U.S. deferred tax balances as a result of tax rate changes. |
||||||||||||||
|
Notes: |
||||||||||||||
|
Consolidated depreciation expense is $205 and $161 in 2021 and 2020, respectively. |
||||||||||||||
|
Base Business Organic Revenue Growth |
|||
|
Three Months |
|||
|
October 2, |
|||
|
2021 |
|||
|
Revenue Growth |
9 |
% |
|
|
COVID-19 Response Revenue (a) (b) |
-2 |
% |
|
|
Base Business Revenue Growth |
11 |
% |
|
|
Acquisitions |
0 |
% |
|
|
Currency Translation |
1 |
% |
|
|
Base Business Organic Revenue Growth |
10 |
% |
|
|
(a) COVID-19 response revenue includes effects of COVID-19 response revenues from acquired businesses and foreign currency translation. |
|||
|
(b) Adjustment to exclude the impact of COVID-19 response revenue. |
|||
|
Condensed Consolidated Statement of Income (unaudited) (a)(b) |
||||||||||||||
|
Nine Months Ended |
||||||||||||||
|
October 2, |
% of |
September 26, |
% of |
|||||||||||
|
(In millions except per share amounts) |
2021 |
Revenues |
2020 |
Revenues |
||||||||||
|
Revenues |
$ |
28,509 |
$ |
21,668 |
||||||||||
|
Costs and Operating Expenses: |
||||||||||||||
|
Cost of revenues (c) |
13,675 |
48.0 |
% |
10,846 |
50.1 |
% |
||||||||
|
Selling, general and administrative expenses (d) |
4,884 |
17.1 |
% |
3,971 |
18.3 |
% |
||||||||
|
Amortization of acquisition-related intangible assets |
1,295 |
4.6 |
% |
1,256 |
5.8 |
% |
||||||||
|
Research and development expenses |
1,014 |
3.6 |
% |
805 |
3.7 |
% |
||||||||
|
Restructuring and other costs (e) |
151 |
0.5 |
% |
67 |
0.3 |
% |
||||||||
|
21,019 |
73.7 |
% |
16,945 |
78.2 |
% |
|||||||||
|
Operating Income |
7,490 |
26.3 |
% |
4,723 |
21.8 |
% |
||||||||
|
Interest Income |
32 |
53 |
||||||||||||
|
Interest Expense |
(375) |
(407) |
||||||||||||
|
Other Expense (f) |
(174) |
(36) |
||||||||||||
|
Income Before Income Taxes |
6,973 |
4,333 |
||||||||||||
|
Provision for Income Taxes (g) |
(906) |
(456) |
||||||||||||
|
Net Income |
$ |
6,067 |
21.3 |
% |
$ |
3,877 |
17.9 |
% |
||||||
|
Earnings per Share: |
||||||||||||||
|
Basic |
$ |
15.41 |
$ |
9.79 |
||||||||||
|
Diluted |
$ |
15.29 |
$ |
9.71 |
||||||||||
|
Weighted Average Shares: |
||||||||||||||
|
Basic |
394 |
396 |
||||||||||||
|
Diluted |
397 |
399 |
||||||||||||
|
Reconciliation of Adjusted Operating Income and Adjusted Operating Margin |
||||||||||||||
|
GAAP Operating Income (a) |
$ |
7,490 |
26.3 |
% |
$ |
4,723 |
21.8 |
% |
||||||
|
Cost of Revenues Charges (c) |
8 |
0.0 |
% |
5 |
0.0 |
% |
||||||||
|
Selling, General and Administrative Charges (Credits) (d) |
33 |
0.1 |
% |
(7) |
0.0 |
% |
||||||||
|
Restructuring and Other Costs (e) |
151 |
0.5 |
% |
67 |
0.3 |
% |
||||||||
|
Amortization of Acquisition-related Intangible Assets |
1,295 |
4.6 |
% |
1,256 |
5.8 |
% |
||||||||
|
Adjusted Operating Income (b) |
$ |
8,977 |
31.5 |
% |
$ |
6,044 |
27.9 |
% |
||||||
|
Reconciliation of Adjusted Net Income |
||||||||||||||
|
GAAP Net Income (a) |
$ |
6,067 |
$ |
3,877 |
||||||||||
|
Cost of Revenues Charges (c) |
8 |
5 |
||||||||||||
|
Selling, General and Administrative Charges (Credits) (d) |
33 |
(7) |
||||||||||||
|
Restructuring and Other Costs (e) |
151 |
67 |
||||||||||||
|
Amortization of Acquisition-related Intangible Assets |
1,295 |
1,256 |
||||||||||||
|
Other Expense (f) |
200 |
79 |
||||||||||||
|
Benefit from Income Taxes (g) |
(380) |
(302) |
||||||||||||
|
Adjusted Net Income (b) |
$ |
7,374 |
$ |
4,975 |
||||||||||
|
Reconciliation of Adjusted Earnings per Share |
||||||||||||||
|
GAAP Diluted EPS (a) |
$ |
15.29 |
$ |
9.71 |
||||||||||
|
Cost of Revenues Charges, Net of Tax (c) |
0.02 |
0.01 |
||||||||||||
|
Selling, General and Administrative Charges (Credits), Net of Tax (d) |
0.04 |
(0.01) |
||||||||||||
|
Restructuring and Other Costs, Net of Tax (e) |
0.29 |
0.13 |
||||||||||||
|
Amortization of Acquisition-related Intangible Assets, Net of Tax |
2.54 |
2.49 |
||||||||||||
|
Other Expense, Net of Tax (f) |
0.43 |
0.15 |
||||||||||||
|
Benefit from Income Taxes (g) |
(0.03) |
(0.02) |
||||||||||||
|
Adjusted EPS (b) |
$ |
18.58 |
$ |
12.46 |
||||||||||
|
Reconciliation of Free Cash Flow |
||||||||||||||
|
GAAP Net Cash Provided by Operating Activities (a) |
$ |
6,855 |
$ |
4,950 |
||||||||||
|
Purchases of Property, Plant and Equipment |
(1,692) |
(888) |
||||||||||||
|
Proceeds from Sale of Property, Plant and Equipment |
9 |
7 |
||||||||||||
|
Free Cash Flow |
$ |
5,172 |
$ |
4,069 |
||||||||||
|
Segment Data |
Nine Months Ended |
|||||||||||||
|
October 2, |
% of |
September 26, |
% of |
|||||||||||
|
(In millions) |
2021 |
Revenues |
2020 |
Revenues |
||||||||||
|
Revenues |
||||||||||||||
|
Life Sciences Solutions |
$ |
11,481 |
40.3 |
% |
$ |
7,800 |
36.0 |
% |
||||||
|
Analytical Instruments |
4,344 |
15.2 |
% |
3,488 |
16.1 |
% |
||||||||
|
Specialty Diagnostics |
4,212 |
14.8 |
% |
3,376 |
15.6 |
% |
||||||||
|
Laboratory Products and Services |
10,667 |
37.4 |
% |
8,629 |
39.8 |
% |
||||||||
|
Eliminations |
(2,195) |
-7.7 |
% |
(1,625) |
-7.5 |
% |
||||||||
|
Consolidated Revenues |
$ |
28,509 |
100.0 |
% |
$ |
21,668 |
100.0 |
% |
||||||
|
Operating Income and Operating Margin |
||||||||||||||
|
Life Sciences Solutions |
$ |
5,818 |
50.7 |
% |
$ |
3,788 |
48.6 |
% |
||||||
|
Analytical Instruments |
816 |
18.8 |
% |
477 |
13.7 |
% |
||||||||
|
Specialty Diagnostics |
983 |
23.3 |
% |
848 |
25.1 |
% |
||||||||
|
Laboratory Products and Services |
1,360 |
12.8 |
% |
931 |
10.8 |
% |
||||||||
|
Subtotal Reportable Segments |
8,977 |
31.5 |
% |
6,044 |
27.9 |
% |
||||||||
|
Cost of Revenues Charges (c) |
(8) |
0.0 |
% |
(5) |
0.0 |
% |
||||||||
|
Selling, General and Administrative (Charges) Credits (d) |
(33) |
-0.1 |
% |
7 |
0.0 |
% |
||||||||
|
Restructuring and Other Costs (e) |
(151) |
-0.5 |
% |
(67) |
-0.3 |
% |
||||||||
|
Amortization of Acquisition-related Intangible Assets |
(1,295) |
-4.6 |
% |
(1,256) |
-5.8 |
% |
||||||||
|
GAAP Operating Income (a) |
$ |
7,490 |
26.3 |
% |
$ |
4,723 |
21.8 |
% |
||||||
|
(a) “GAAP” (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP). |
||||||||||||||
|
(b) Adjusted results are non-GAAP measures and, for income measures, exclude certain charges to cost of revenues (see note (c) for details); certain credits/charges to selling, general and administrative expenses (see note (d) for details); amortization of acquisition-related intangible assets; restructuring and other costs (see note (e) for details); certain other gains or losses that are either isolated or cannot be expected to occur again with any predictability (see note (f) for details); and the tax consequences of the preceding items and certain other tax items (see note (g) for details). |
||||||||||||||
|
(c) Reported results in 2021 include charges for the sale of inventories revalued at the date of acquisition. Reported results in 2020 include $2 of charges to conform the accounting policies of a recently acquired business with the company’s accounting policies and $3 of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. |
||||||||||||||
|
(d) Reported results in 2021 and 2020 include certain third-party expenses (credits), principally transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions; credits for changes in estimates of contingent acquisition consideration; and charges associated with product liability litigation. |
||||||||||||||
|
(e) Reported results in 2021 and 2020 include restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations, and charges for impairment of acquired technology. Reported results in 2021 include $13 of charges for compensation contractually due to employees of acquired businesses at the date of acquisition; $3 of net charges for pre-acquisition related matters; offset in part by $4 of credits for the settlement of environmental-related matters. |
||||||||||||||
|
(f) Reported results in 2021 and 2020 include gains on investments and charges associated with entering hedging contracts and amortization of bridge loan commitment fees for pending/terminated acquisitions. Reported results in 2021 include $197 of losses on the early extinguishment of debt. Reported results in 2020 include $6 of net charges for the settlement/curtailment of pension plans. |
||||||||||||||
|
(g) Reported provision for income taxes in 2021 and 2020 includes incremental tax benefit for the pre-tax reconciling items between GAAP and adjusted net income and $12 and $5 of incremental tax benefit, respectively, from adjusting the company’s non-U.S. deferred tax balances as a result of tax rate changes. Reported results in 2020 also include $2 of incremental tax benefit from audit settlements. |
||||||||||||||
|
Notes: |
||||||||||||||
|
Consolidated depreciation expense is $614 and $467 in 2021 and 2020, respectively. |
||||||||||||||
|
Condensed Consolidated Balance Sheet (unaudited) |
||||||||
|
October 2, |
December 31, |
|||||||
|
(In millions) |
2021 |
2020 |
||||||
|
Assets |
||||||||
|
Current Assets: |
||||||||
|
Cash and cash equivalents |
$ |
12,027 |
$ |
10,325 |
||||
|
Accounts receivable, net |
5,557 |
5,741 |
||||||
|
Inventories |
4,906 |
4,029 |
||||||
|
Other current assets |
2,234 |
1,862 |
||||||
|
Total current assets |
24,724 |
21,957 |
||||||
|
Property, Plant and Equipment, Net |
7,049 |
5,912 |
||||||
|
Acquisition-related Intangible Assets, Net |
11,927 |
12,685 |
||||||
|
Other Assets |
2,991 |
2,457 |
||||||
|
Goodwill |
26,909 |
26,041 |
||||||
|
Total Assets |
$ |
73,600 |
$ |
69,052 |
||||
|
Liabilities and Shareholders’ Equity |
||||||||
|
Current Liabilities: |
||||||||
|
Short-term obligations and current maturities of long-term obligations |
$ |
19 |
$ |
2,628 |
||||
|
Other current liabilities |
7,734 |
7,676 |
||||||
|
Total current liabilities |
7,753 |
10,304 |
||||||
|
Other Long-term Liabilities |
5,449 |
5,134 |
||||||
|
Long-term Obligations |
21,688 |
19,107 |
||||||
|
Total Shareholders’ Equity |
38,710 |
34,507 |
||||||
|
Total Liabilities and Shareholders’ Equity |
$ |
73,600 |
$ |
69,052 |
||||
|
Condensed Consolidated Statement of Cash Flows (unaudited) |
||||||||
|
Nine Months Ended |
||||||||
|
October 2, |
September 26, |
|||||||
|
(In millions) |
2021 |
2020 |
||||||
|
Operating Activities |
||||||||
|
Net income |
$ |
6,067 |
$ |
3,877 |
||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation and amortization |
1,909 |
1,723 |
||||||
|
Change in deferred income taxes |
(455) |
(496) |
||||||
|
Other non-cash expenses, net |
544 |
354 |
||||||
|
Changes in assets and liabilities, excluding the effects of acquisitions and disposition |
(1,210) |
(508) |
||||||
|
Net cash provided by operating activities |
6,855 |
4,950 |
||||||
|
Investing Activities |
||||||||
|
Acquisitions, net of cash acquired |
(1,519) |
(3) |
||||||
|
Purchases of property, plant and equipment |
(1,692) |
(888) |
||||||
|
Proceeds from sale of property, plant and equipment |
9 |
7 |
||||||
|
Other investing activities, net |
(38) |
— |
||||||
|
Net cash used in investing activities |
(3,240) |
(884) |
||||||
|
Financing Activities |
||||||||
|
Net proceeds from issuance of debt |
3,122 |
3,464 |
||||||
|
Repayment of debt |
(2,807) |
(712) |
||||||
|
Net proceeds from issuance of commercial paper |
— |
383 |
||||||
|
Repayment of commercial paper |
— |
(387) |
||||||
|
Purchases of company common stock |
(2,000) |
(1,500) |
||||||
|
Dividends paid |
(292) |
(250) |
||||||
|
Net proceeds from issuance of company common stock under employee stock plans |
101 |
156 |
||||||
|
Other financing activities, net |
(10) |
(146) |
||||||
|
Net cash (used in) provided by financing activities |
(1,886) |
1,008 |
||||||
|
Exchange Rate Effect on Cash |
(17) |
74 |
||||||
|
Increase in Cash, Cash Equivalents and Restricted Cash |
1,712 |
5,148 |
||||||
|
Cash, Cash Equivalents and Restricted Cash at Beginning of Period |
10,336 |
2,422 |
||||||
|
Cash, Cash Equivalents and Restricted Cash at End of Period |
$ |
12,048 |
$ |
7,570 |
||||
|
Free Cash Flow (a) |
$ |
5,172 |
$ |
4,069 |
||||
|
(a) Free cash flow is net cash provided by operating activities less net purchases of property, plant and equipment. |
||||||||
SOURCE Thermo Fisher Scientific
